Appendix Table E32. Phenotypic test details in studies assessing the predictive ability of VerifyNow in patients with cerebrovascular disease

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author, year [ref]****UID****Country****Study Name** | **Test/Device name** **Device category Device name & manufacturer\*** | **Agonist used** | **Sample Collection and Procurement****Anticoagulant used****Interval between clopidogrel doses and blood sampling (in days)** **Interval between sampling and testing (in days):** | **Grouping of Phenotypes\*\* [Definition]**  | **Rational for the grouping of phenotypes reported (Yes/No)** **[short description]** | **Frequency of phenotypes**  |
| Ryu, 201021113358South KoreaNR | VerifyNow P2Y12 assayNRAccumetrics Inc | NR | NRNRTest conducted after taking the medicine for 3 daysNR | platelet inhibition < 40% (clopidogrel resistance)platelet inhibition >/= 40% (clopidogrel nonresistance) | Not explicitly reported. | platelet inhibition < 40% (clopidogrel resistance): 33/53 (62.3%)platelet inhibition >/= 40% (clopidogrel nonresistance): 20/53 (37.7%) |
| Kang, 201020223886South KoreaNR | VerifyNow P2Y12 assay/Turbidimetric basedoptical detection systemVerifyNow P2Y12 assayAccumetrics, San Diego, California | 20 μmol of ADP | Whole blood was obtained before the coil embolization3.2% sodium citrateNR [Clopidogrel came first]NR | First quartile (<240 PRU)Second quartile (240-284 PRU) Third quartile (285-332 PRU) Fourth quartile (>332 PRU) | Not explicitly reported. | First quartile (<240 PRU): 47 (25.3%)Second quartile (240-284 PRU): 46 (24.7%)Third quartile (285-332 PRU): 46 (24.7%)Fourth quartile (>332 PRU): 47 (25.3%) |
| Drazin, 201121990814USNR | VerifyNowP2Y12assayNRAccumetrics | ADP | NRHeparinClopidogrel given at least 12 hr before stenting and measurements taken intraoperativelyNR | Suboptimal clopidogrel response (<20% P2Y12 platelet inhibition), measured intraoperativelyOptimal responders, measured intraoperatively | Not explicitly reported. | Suboptimal clopidogrel response (<20% P2Y12 platelet inhibition), measured intraoperatively: 19/52 (37%)Optimal responders, measured intraoperatively: 33/52 (63%) |

**Abbreviations:** ADP= adenosine 5’-diphosphate; Ag= aggregation; PGE1=prostaglandin; ROC=receiver operating characteristic; AUC=area under the curve; IPA= inhibition of platelet aggregation; LTA= light transmission aggregometry; MEA= multiple electrode platelet aggregometry; PFA= platelet function analysis; TEG=thromboelastography; sTEG=short thromboelastography; VASP = vasodilator-stimulated phosphoprotein; VASP-FCT=vasodilator-stimulated phosphoprotein flow cytometry; CEPI=collagen-epinephrine ; CADP=collagen-ADP; CT=closure times; HCPR=high on-clopidogrel platelet reactivity; PCI = percutaneous coronary intervention; RPA= residual platelet aggregation; GP= glycoprotein; HRP=high platelet reactivity; NPR=normal on-treatment platelet reactivity; HPPR= high post-treatment platelet reactivity; MPA= maximum platelet aggregation; RPR= residual platelet reactivity; OTPR=on-treatment platelet reactivity; DPAI= degree of platelet aggregation inhibition; PRU=P2Y12 reaction units; CRP=C-reaction protein; PRI=platelet reactivity index; LR=low responder; IQR=interquartile range; AA= arachidonic acid; LD=loading dose; MD=maintain dose; SD=standard deviation; NR=not reported